FDA Brief

Company record

Sagent Pharmaceuticals, Inc.

1 FDA warning letter since 2023 and 1 recall in the last 12 months.

Get an email the day FDA posts anything new about Sagent Pharmaceuticals, Inc..

Warning letters

  1. Sagent Pharmaceuticals, Inc.

    FDA found SterRx, acquired by Sagent, made sterile drugs under conditions that risked contamination and lacked sterility assurance.

    High risk

Recalls

ReportedClassFirmProduct and reason
May 27 Class III Sagent Pharmaceuticals
Drug
Busulfan Injection, 60 mg per 10 mL (6 mg per mL), 8x10 mL Single-Dose Vials, Rx only, Mfd. for Sagent Pharmaceuticals, Schaumburg, IL 60195, Made in Canada, NDC 25021-241-10.
Failed Impurities/Degradation Specifications